Laboratoire HRA Pharma SA

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- The intrauterine contraceptive devices (IUD) market is estimated to grow by USD 965.49 million from 2023 to 2027 at a CAGR of 3.98% according to Technavio. AbbVie Inc., Bayer AG, DKT International, Durbin PLC, EurimPharm Arzneimittel GmbH, EUROGINE SL, Gima Spa, HLL Lifecare Ltd., Krishco Medical Products Pvt. Ltd., Laboratoire HRA Pharma SAS, Melbea Innovations Ltd., Meril Life Sciences Pvt. Ltd., Ocon Medical Ltd., Pregna International Ltd, Prosan International BV, SMB Corp. of India, TESPRO LLC, The Cooper Companies Inc., TRIMEDIC SUPPLY NETWORK Ltd., and Viatris Inc. are key companies. The Abbvie company offers intrauterine contraceptive devices such as the LILETTA (levonorgestrel-releasing) intrauterine contraceptive. Continue Reading Technavio has announced its latest market research report titled Global Intrauterine Contraceptive Devices (IUD) Market 2023-2027 To understand more about the information services market, request a Free sample report The long-term efficacy and increased acceptance of IUDs is a major trend in the market. Global unintended pregnancy rates have declined since the 1990s but remain high and vary across regions. Developed regions have seen faster declines than developing ones. Reduced unplanned pregnancies have lowered abortion rates. Reduced stigma on birth control has led to couples seeking control over childbirth timing and spacing for financial and maternal health reasons. IUDs help space births by preventing unintended pregnancies. Increased awareness of family planning significance leads to higher contraceptive adoption and improved healthcare outcomes for mothers and babies. North America is projected to contribute 33% of market growth by 2027. The US dominates the market in the region due to local market players, government support, high awareness, and technological innovations like postpartum and reusable IUDs, fueling market growth. Initiatives by government and non-profit organizations are a key factor driving market growth. Adverse effects of IUDs is a significant challenge restricting market growth. Drivers, Trends, and Challenges have an impact on market dynamics and can impact businesses. Find some insights from a free sample report! Why Buy? Add credibility to strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio- Buy the Report What are the key data covered in this Intrauterine Contraceptive Devices (IUD) Market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth between 2023 and 2027 Precise estimation of the size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth across North America, Europe, APAC, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of companies Technavio's SUBSCRIPTION platform Intrauterine Contraceptive Devices (IUD): Overview Intrauterine contraceptive devices (IUDs) are small, T-shaped devices inserted into the uterus to prevent pregnancy. They are a popular form of long-acting reversible contraception (LARC) and offer effective birth control for women. IUDs work by either releasing hormones (hormonal IUDs) or creating a physical barrier to sperm (copper IUDs), providing reliable contraception for several years. They are a key component of women's reproductive health and family planning, offering a safe and convenient option for birth control. The IUD market continues to grow as more women opt for this effective and long-term contraceptive method. Related Reports The Female Contraceptive Market is estimated to grow at a CAGR of 5.32% between 2022 and 2027. The size of the market is forecast to increase by USD 5,142.22 million. The aesthetic devices market size is estimated to grow by USD 10,815.68 million at a CAGR of 11.22% between 2022 and 2027. ToC: Executive Summary Market Landscape Market Sizing Historic Sizes Five Forces Analysis Segmentation by End-user Segmentation by Type Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

The FDA on Thursday approved Perrigo's Opill (norgestrel) for over-the-counter (OTC) use, making it the first hormonal oral contraceptive available in the US without a prescription. "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available non-prescription contraceptive methods in preventing unintended pregnancy," stated Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.Roughly half the 6.1 million pregnancies in the US each year are unplanned, according to the FDA. It said the OTC approval "is expected to remove barriers to access and reduce the risk of unintended pregnancies."The progestin-only drug was initially approved by the FDA for prescription use in 1973. The latest decision followed a 17-0 advisory panel vote earlier this year in favour of recommending Opill for approval despite questions over some data on its proper use. These included whether women with certain medical conditions that would ordinarily preclude them from taking oral contraceptives – such as those with breast cancer and undiagnosed vaginal bleeding – will follow the warnings and avoid the product.FDA scientists also questioned whether younger people and people with limited literacy would be able to properly follow the dosing directions. In addition, agency staff suggested that researchers likely used methods that exaggerated positive results for the drug.However, in its decision Thursday, the FDA said that studies showed that consumer understanding of information on Opill's drug facts label was "high overall and that a high proportion of consumers understood the label instructions, supporting their ability to properly use the drug when it is available as an [OTC] product." The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating. The agency noted that Opill is not for use as emergency contraception and does not prevent pregnancy after unprotected sex.Expected launch in early 2024The approval of Opill was granted to Laboratoire HRA Pharma, which was acquired by Perrigo last year for €1.8 billion ($2 billion). The company said the contraceptive would be available for purchase by early 2024, but would not provide specifics about pricing. However, Frédérique Welgryn, Perrigo's global vice president for women's health, said the company was committed to making the drug "accessible and affordable to women and people of all ages," adding it would also set up a consumer assistance programme to provide Opill at no cost to some women.Meanwhile, under a recent executive order by President Joe Biden, the federal government could soon take steps toward requiring insurers to cover OTC oral contraceptive medications.The FDA approval comes nearly three months after the Supreme Court blocked a controversial lower court order challenging access to the abortion drug mifepristone. The lower court sought to restrict access to mifepristone, after a district court judge in Texas ruled to toss the FDA's approval of the drug, which had been cleared for more than 20 years.

SILVER SPRING, Md., July 13, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online. The timeline for availability and price of this nonprescription product is determined by the manufacturer. Other approved formulations and dosages of other oral contraceptives will remain available by prescription only. "Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research. "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy." Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider. Almost half of the 6.1 million pregnancies in the U.S. each year are unintended. Unintended pregnancies have been linked to negative maternal and perinatal outcomes, including reduced likelihood of receiving early prenatal care and increased risk of preterm delivery, with associated adverse neonatal, developmental and child health outcomes. Availability of nonprescription Opill may help reduce the number of unintended pregnancies and their potential negative impacts. The contraceptive efficacy of norgestrel was established with the original approval for prescription use in 1973. HRA Pharma applied to switch norgestrel from a prescription to an over-the-counter product. For approval of a product for use in the nonprescription setting, the FDA requires that the applicant demonstrate that the product can be used by consumers safely and effectively, relying only on the nonprescription drug labeling without any assistance from a health care professional. Studies showed that consumer understanding of information on the Opill Drug Facts label was high overall and that a high proportion of consumers understood the label instructions, supporting their ability to properly use the drug when it is available as an over-the-counter product. When properly used, Opill is safe and effective. Opill should be taken at the same time every day; adherence to daily use at the same time of day is important for the effectiveness of Opill. Using medications that interact with Opill can result in decreased efficacy of Opill or the other medication, or both, potentially resulting in unintended pregnancy. The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating. Opill should not be used by those who have or have ever had breast cancer. Consumers who have any other form of cancer should ask a doctor before use. Opill also should not be used together with another hormonal birth control product such as another oral contraceptive tablet, a vaginal ring, a contraceptive patch, a contraceptive implant, a contraceptive injection or an IUD (intra-uterine device). Use of Opill may be associated with changes in vaginal bleeding patterns, such as irregular spotting and prolonged bleeding. Consumers should inform a health care provider if they develop repeated vaginal bleeding after sex, or prolonged episodes of bleeding or amenorrhea (absence of menstrual period). Individuals who miss two periods (or have missed a single period and have missed doses of Opill) or suspect they may be pregnant should take a pregnancy test. Consumers should discontinue Opill if pregnancy is confirmed. Opill is not for use as emergency contraception and does not prevent pregnancy after unprotected sex. Oral contraceptives do not protect against transmission of HIV, AIDS and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. Condoms should be used to prevent sexually transmitted diseases. The FDA granted the approval to Laboratoire HRA Pharma, recently acquired by Perrigo Company plc. Related Information Drugs@FDA: Opill Decisional Memo Opill (0.075mg Oral Norgestrel Tablet) Information The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.